Expression, purification and enzymatic characterization of Brugia malayi dihydrofolate reductase.

Protein Expr Purif 2016 12 18;128:81-5. Epub 2016 Aug 18.

Department of Chemistry and Biochemistry, Montclair State University, 1 Normal Avenue, Montclair, NJ, 07043, USA. Electronic address:

Brugia malayi (B. malayi) is one of the three causative agents of lymphatic filariasis, a neglected parasitic disease. Current literature suggests that dihydrofolate reductase is a potential drug target for the elimination of B. malayi. Here we report the recombinant expression and purification of a ∼20 kDa B. malayi dihydrofolate reductase (BmDHFR). A His6-tagged construct was expressed in E. coli and purified by affinity chromatography to yield active and homogeneous enzyme for steady-state kinetic characterization and inhibition studies. The catalytic activity kcat was found to be 1.4 ± 0.1 s(-1), the Michaelis Menten constant KM for dihydrofolate 14.7 ± 3.6 μM, and the equilibrium dissociation constant KD for NADPH 25 ± 24 nM. For BmDHFR, IC50 values for a six DHFR inhibitors were determined to be 3.1 ± 0.2 nM for methotrexate, 32 ± 22 μM for trimethoprim, 109 ± 34 μM for pyrimethamine, 154 ± 46 μM for 2,4-diaminoquinazoline, 771 ± 44 μM for cycloguanil, and >20,000 μM for 2,4-diaminopyrimidine. Our findings suggest that antifolate compounds can serve as inhibitors of BmDHFR.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pep.2016.08.012DOI Listing
December 2016

Publication Analysis

Top Keywords

dihydrofolate reductase
12
expression purification
8
brugia malayi
8
kcat 14 ± 01
4
activity kcat
4
studies catalytic
4
inhibition studies
4
catalytic activity
4
s-1 michaelis
4
dihydrofolate 147 ± 36 μm
4
147 ± 36 μm equilibrium
4
constant dihydrofolate
4
menten constant
4
characterization inhibition
4
michaelis menten
4
14 ± 01 s-1
4
enzyme steady-state
4
expressed e coli
4
e coli purified
4
construct expressed
4

Similar Publications

Expression, purification, and inhibition profile of dihydrofolate reductase from the filarial nematode Wuchereria bancrofti.

PLoS One 2018 22;13(5):e0197173. Epub 2018 May 22.

Department of Chemistry and Biochemistry, Montclair State University, Montclair, NJ, United States of America.

Filariasis is a tropical disease caused by the parasitic nematodes Wuchereria bancrofti and Brugia malayi. Known inhibitors of dihydrofolate reductase (DHFR) have been previously shown to kill Brugia malayi nematodes and to inhibit Brugia malayi DHFR (BmDHFR) at nanomolar concentrations. These data suggest that BmDHFR is a potential target for the treatment of filariasis. Read More

View Article and Full-Text PDF
July 2018

Molecular cloning, purification and characterization of Brugia malayi phosphoglycerate kinase.

Protein Expr Purif 2017 04 10;132:152-163. Epub 2017 Feb 10.

Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, India. Electronic address:

Phosphoglycerate kinase (PGK) is a glycolytic enzyme present in many parasites. It has been reported as a candidate molecule for drug and vaccine developments. In the present study, a full-length cDNA encoding the Brugia malayi 3-phosphoglycerate kinase (BmPGK) with an open reading frame of 1. Read More

View Article and Full-Text PDF
April 2017

In vitro biological evaluation of biguanides and dihydrotriazines against Brugia malayi and folate reversal studies.

Acta Trop 2010 Jan 19;113(1):48-51. Epub 2009 Sep 19.

Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga (E), Mumbai 400019, India.

Dihydrofolate reductase (DHFR) is a well-known target for antibacterial and anticancer therapy. DHFR inhibitors are useful for protozoan parasites, but are yet to be explored against metazoan species; hence the present work was designed to evaluate the efficacy of DHFR inhibitors against filariasis, one of the major neglected tropical diseases. Molecules from our in-house library of synthetic antifolate agents (biguanide and dihydrotriazine derivatives) were evaluated along with the antimalarial drug pyrimethamine and the antibacterial drug trimethoprim in an in vitro model against Brugia malayi microfilariae (Mf). Read More

View Article and Full-Text PDF
January 2010

UDP-galactopyranose mutase, a potential drug target against human pathogenic nematode Brugia malayi.

Pathog Dis 2016 08 26;74(6). Epub 2016 Jul 26.

Academy of Scientific and Innovative Research (AcSIR), Anusandhan Bhawan, New Delhi-110001, India Division of Parasitology, CSIR-Central Drug Research Institute, BS 10/1, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow-226031, India

Lymphatic filariasis, a vector-borne neglected tropical disease affects millions of population in tropical and subtropical countries. Vaccine unavailability and emerging drug resistance against standard antifilarial drugs necessitate search of novel drug targets for developing alternate drugs. Recently, UDP-galactopyranose mutases (UGM) have emerged as a promising drug target playing an important role in parasite virulence and survival. Read More

View Article and Full-Text PDF
August 2016